Functional Genomics for Cancer Drug Target Discovery

被引：47
|
作者：
Haley, Benjamin [1 ]
Roudnicky, Filip [2 ]
机构：
[1] Genentech Inc, Mol Biol Dept, 1 DNA Way, San Francisco, CA 94080 USA
[2] F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Pharmaceut Res & Early Dev, CH-4070 Basel, Switzerland
来源：
CANCER CELL | 2020年 / 38卷 / 01期
关键词：
LARGE-SCALE; SYNTHETIC LETHALITY; CRISPR-CAS9; SCREENS; GENE ESSENTIALITY; RNAI; SHRNA; GUIDE; IDENTIFICATION; CRISPR/CAS9; MUTAGENESIS;
D O I：
10.1016/j.ccell.2020.04.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Functional genomics describes a field of biology that uses a range of approaches for assessing gene function with high-throughput molecular, genetic, and cellular technologies. The near limitless potential for applying these concepts to study the activities of all genetic loci has completely upended how today's cancer biologists tackle drug target discovery. We provide an overview of contemporary functional genomics platforms, highlighting areas of distinction and complementarity across technologies, so as to aid in the development or interpretation of cancer-focused screening efforts.
引用
收藏
页码：31 / 43
页数：13
相关论文
共 50 条
  • [41] Enhancing knowledge discovery from cancer genomics data with Galaxy
    Albuquerque, Marco A.
    Grande, BrunoM.
    Ritch, Elie J.
    Pararajalingam, Prasath
    Jessa, Selin
    Krzywinski, Martin
    Grewal, Jasleen K.
    Shah, Sohrab P.
    Boutros, Paul C.
    Morin, Ryan D.
    GIGASCIENCE, 2017, 6 (05):
  • [42] Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer
    Tang, Yew Chung
    Ho, Szu-Chi
    Tan, Elisabeth
    Ng, Alvin Wei Tian
    McPherson, John R.
    Goh, Germaine Yen Lin
    Teh, Bin Tean
    Bard, Frederic
    Rozen, Steven G.
    BREAST CANCER RESEARCH, 2018, 20
  • [43] UCLA's Molecular Screening Shared Resource: Enhancing Small Molecule Discovery with Functional Genomics and New Technology
    Damoiseaux, Robert
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2014, 17 (04) : 356 - 368
  • [44] Functional Interrogation of Enhancer Connectome Prioritizes Candidate Target Genes at Ovarian Cancer Susceptibility Loci
    Wang, Wei
    Song, Fengju
    Feng, Xiangling
    Chu, Xinlei
    Dai, Hongji
    Tian, Jing
    Fang, Xuan
    Song, Fangfang
    Liu, Ben
    Li, Lian
    Li, Xiangchun
    Zhao, Yanrui
    Zheng, Hong
    Chen, Kexin
    FRONTIERS IN GENETICS, 2021, 12
  • [45] Leveraging Big Data to Transform Target Selection and Drug Discovery
    Chen, B.
    Butte, A. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (03) : 285 - 297
  • [46] The power of combining phenotypic and target-focused drug discovery
    Heilker, Ralf
    Lessel, Uta
    Bischoff, Daniel
    DRUG DISCOVERY TODAY, 2019, 24 (02) : 526 - 532
  • [47] Functional genomics and transcriptomics of prostate cancer: promises and limitations
    Kallioniemi, O
    BJU INTERNATIONAL, 2005, 96 : 10 - 15
  • [48] From target discovery to clinical drug development with human genetics
    Trajanoska, Katerina
    Bherer, Claude
    Taliun, Daniel
    Zhou, Sirui
    Richards, J. Brent
    Mooser, Vincent
    NATURE, 2023, 620 (7975) : 737 - 745
  • [49] Functional Genomic Characterization of Cancer Genomes
    Howard, Thomas P.
    Vazquez, Francisca
    Tsherniak, AvIAD
    Hong, Andrew L.
    Rinne, Mik
    Aguirre, Andrew J.
    Boehm, Jesse S.
    Hahn, William C.
    TARGETING CANCER, VOL 81, 2016, 2016, 81 : 237 - 246
  • [50] 'Big data' approaches for novel anti-cancer drug discovery
    Benstead-Hume, Graeme
    Wooller, Sarah K.
    Pearl, Frances M. G.
    EXPERT OPINION ON DRUG DISCOVERY, 2017, 12 (06) : 599 - 609
12345